{
  "id": "61f7d15d882a024a10000031",
  "type": "list",
  "question": "Which drugs are included in the Contrave pill?",
  "ideal_answer": "Contrave\u00ae is an adjunct pharmacotherapy for obesity that contains bupropion (BUP) and naltrexone (NTX).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28130024",
    "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
    "http://www.ncbi.nlm.nih.gov/pubmed/19885278",
    "http://www.ncbi.nlm.nih.gov/pubmed/26679384",
    "http://www.ncbi.nlm.nih.gov/pubmed/26105116",
    "http://www.ncbi.nlm.nih.gov/pubmed/25258511",
    "http://www.ncbi.nlm.nih.gov/pubmed/30991059",
    "http://www.ncbi.nlm.nih.gov/pubmed/26957883",
    "http://www.ncbi.nlm.nih.gov/pubmed/34745784",
    "http://www.ncbi.nlm.nih.gov/pubmed/25395816",
    "http://www.ncbi.nlm.nih.gov/pubmed/27773782",
    "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
    "http://www.ncbi.nlm.nih.gov/pubmed/20509712",
    "http://www.ncbi.nlm.nih.gov/pubmed/19777400",
    "http://www.ncbi.nlm.nih.gov/pubmed/29408463",
    "http://www.ncbi.nlm.nih.gov/pubmed/29151591",
    "http://www.ncbi.nlm.nih.gov/pubmed/22860172"
  ],
  "snippets": [
    {
      "text": "Bupropion is indicated for major depressive disorder (Wellbutrin\u00ae, GlaxoSmithKline, Research Triangle Park, NC), smoking cessation (Zyban\u00ae, GlaxoSmithKline, Research Triangle Park, NC), and weight loss (when in formulation with naltrexone ER; Contrave\u00ae, Orixegen Therapeutics, La Jolla, CA). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34745784",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A fixed dose combination of bupropion (BPP) and naltrexone (NTX), Contrave\u00ae, is an FDA approved pharmacotherapy for the treatment of obesity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30991059",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: We examined coverage for phentermine, diethylpropion, phendimetrazine, Benzphentamine, Lorcaserin, Phentermine/Topiramate (Qysmia), Liraglutide (Saxenda) and Buproprion/Naltrexone (Contrave) among Medicare, Medicaid and marketplace insurance plans in 34 states.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29151591",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave\u00ae is an adjunct pharmacotherapy for obesity that contains bupropion (BUP) and naltrexone (NTX). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29408463",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "THODS: We examined coverage for phentermine, diethylpropion, phendimetrazine, Benzphentamine, Lorcaserin, Phentermine/Topiramate (Qysmia), Liraglutide (Saxenda) and Buproprion/Naltrexone (Contrave) among Medicare, Medicaid and marketplace insurance plans in 34 states.RE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29151591",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include combinations (at low dose) of existing drugs, e.g., bupropion + naltrexone (Contrave), phentermine + topiramate (Qsymia), higher doses of existing drugs licensed for other indications (liraglutide, 3 mg), and new entities (lorcaserin).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CENT FINDINGS: Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications available for the treatment of obesity. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four combination agent compounds in late stage development include (1) Contrave, which combines long-acting versions of naltrexone and bupropion; (2) Empatic, which combines long-acting bupropion and long-acting zonisamide; (3) Qnexa, which combines phentermine with controlled release topiramate; and (4) an injectable combination of leptin and pramlintide.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19885278",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22860172",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification. I",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A fixed dose combination of bupropion (BPP) and naltrexone (NTX), Contrave\u00ae, is an FDA approved pharmacotherapy for the treatment of obesity. A re",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30991059",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone. T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ts have been approved by the FDA to treat obesity, including phentermine/topiramate (Qsymia\u00ae) and naltrexone/bupropion (Contrave\u00ae). The current review provides an ove",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27773782",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20509712",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: We report a case of erythrodermic pustular psoriasis associated with initiation of bupropion/naltrexone (Contrave\u00ae; Orexigen Therapeutics, La Jolla, CA) in a patient with no history of pso",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130024",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "view presented here focuses on naltrexone sustained-release/bupropion sustained-release combination (Contrave(\u00ae)). We conclude ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25258511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Naltrexone/bupropion (Contrave) for weight management; pembrolizumab (Keytruda) for melanoma; dolutegravir/abacavir/lamivudine (Triumeq) for HIV-1; and immune globulin infusion 10% (human) with recombinant human hyaluronidase (Hyqvia) for primary immunodeficiency",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25395816",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave\u00ae is an adjunct pharmacotherapy for obesity that contains bupropion (BUP) and naltrexone (NTX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29408463",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19777400",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22860172",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Contrave(\u00ae) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26679384",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957883",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20509712",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26957883",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20509712",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ns are prescribed. Current antiobesity medications and pharmacological strategies will be reviewed.RECENT FINDINGS: Two new antiobesity drugs - naltrexone/bupropion (Contrave) and liraglutide (Saxenda) - were approved by the US Food and Drug Administration in 2014 and join four other approved obesity medications, including phentermine/topiramate XR (Qsymia) and lorcaserin (Belviq), to form the largest number of medications ava",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26313898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave(\u00ae), Mysimba(\u2122)) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of \u2265 30 kg/m(2) (i.e.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26105116",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "bupropion, naltrexone"
}